Abstract
Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimers disease (AD) in Europe on 17th May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]. In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine.
Current Neuropharmacology
Title: Pharmacodynamics of Memantine: An Update
Volume: 6 Issue: 1
Author(s): C. G. Parsons, G. Rammes and W. Danysz
Affiliation:
Abstract: Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimers disease (AD) in Europe on 17th May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]. In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side effect profile of memantine.
Export Options
About this article
Cite this article as:
Parsons G. C., Rammes G. and Danysz W., Pharmacodynamics of Memantine: An Update, Current Neuropharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157015908783769671
DOI https://dx.doi.org/10.2174/157015908783769671 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome
Current Cardiology Reviews Editors Perspective (Throwing Caution to the Wnts)
Current Neurovascular Research Conjugates of Natural Compounds with Nitroxyl Radicals as a Basis for Creation of Pharmacological Agents of New Generation
Current Medicinal Chemistry Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Cross-talk between Cellular Stress, Cell Cycle and Anticancer Agents: Mechanistic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews AMPK As A Target in Rare Diseases
Current Drug Targets PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Mitochondrial Dysfunction during Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets NPY and NPY Receptors in Vascular Remodeling
Current Topics in Medicinal Chemistry Prostacyclin Synthase Gene: Genetic Polymorphisms and Prevention of Some Cardiovascular Diseases
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy